These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37528470)

  • 1. DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma.
    Kerdivel G; Amrouche F; Calmejane MA; Carallis F; Hamroune J; Hantel C; Bertherat J; Assié G; Boeva V
    Clin Epigenetics; 2023 Aug; 15(1):121. PubMed ID: 37528470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Assessment of
    Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
    Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a CpG island methylator phenotype in adrenocortical carcinomas.
    Barreau O; Assié G; Wilmot-Roussel H; Ragazzon B; Baudry C; Perlemoine K; René-Corail F; Bertagna X; Dousset B; Hamzaoui N; Tissier F; de Reynies A; Bertherat J
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E174-84. PubMed ID: 23093492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
    Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
    Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma.
    Gu P; Zeng Y; Ma W; Zhang W; Liu Y; Guo F; Ruan X; Chi J; Zheng X; Gao M
    Front Endocrinol (Lausanne); 2022; 13():1008301. PubMed ID: 36353231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the etiology and role in oncogenic transformation of the CpG island methylator phenotype: a pan-cancer analysis.
    Yates J; Boeva V
    Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35134107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
    Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
    Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
    Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
    Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients.
    Fu T; Liu Y; Li K; Wan W; Pappou EP; Iacobuzio-Donahue CA; Kerner Z; Baylin SB; Wolfgang CL; Ahuja N
    Oncotarget; 2016 Dec; 7(52):86480-86489. PubMed ID: 27880934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG island methylator phenotype (CIMP) in cancer: causes and implications.
    Teodoridis JM; Hardie C; Brown R
    Cancer Lett; 2008 Sep; 268(2):177-86. PubMed ID: 18471961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological significance of the CpG island methylator phenotype.
    Suzuki H; Yamamoto E; Maruyama R; Niinuma T; Kai M
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):35-42. PubMed ID: 25016183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
    Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
    PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.
    Bae JM; Kim JH; Kang GH
    Histol Histopathol; 2013 May; 28(5):585-95. PubMed ID: 23341177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.
    Ogino S; Odze RD; Kawasaki T; Brahmandam M; Kirkner GJ; Laird PW; Loda M; Fuchs CS
    Am J Surg Pathol; 2006 Sep; 30(9):1175-83. PubMed ID: 16931963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas.
    Arai E; Gotoh M; Tian Y; Sakamoto H; Ono M; Matsuda A; Takahashi Y; Miyata S; Totsuka H; Chiku S; Komiyama M; Fujimoto H; Matsumoto K; Yamada T; Yoshida T; Kanai Y
    Int J Cancer; 2015 Dec; 137(11):2589-606. PubMed ID: 26061684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
    McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
    BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
    Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
    Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
    Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
    Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis.
    Liu JB; Zhang YX; Zhou SH; Shi MX; Cai J; Liu Y; Chen KP; Qiang FL
    World J Gastroenterol; 2011 Nov; 17(42):4718-24. PubMed ID: 22180715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.